Treace Medical Concepts, Inc. (TMCI) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Lilia-Celine Lozada
JPMorgan Chase & Co, Research Division

Good morning, everyone. I’m Lily Lozada. I’m on the med tech team here at JPMorgan. Very happy to have the Treace team with us here today to kick off Wednesday. John is going to do a bit of a presentation for us, and then we’ll jump into some Q&A.

John Treace
Founder, Chairman & CEO

Thanks, Lily, and good morning, everybody. Thanks for joining us today. It’s certainly great to be here at the JPMorgan Healthcare Conference and have some time to talk about Treace Medical. Safe harbor disclosures are here. Please refer to our SEC filings on our website for detailed presentations of risks.

Treace Medical is a medical device company with a focused mission to improve surgical outcomes for bunion patients. Since our IPO in 2021, we continue to execute on our strategic plans, resulting in strong market share gains and encouraging adjusted EBITDA progress. With continued gains across our key operating metrics, this reaffirms our belief that we have the right strategies in place to expand market penetration with our differentiated technologies.

We are the bunion experts. In 2015, we pioneered and commercialized the Lapiplasty 3D bunion correction procedure to bring a better solution to surgeons and deliver better outcomes for patients. Our innovative 3D bunion solutions are backed by strong IP, marketed by the industry’s only bunion-focused direct sales channel and have established Treace Medical as the largest dollar share player in the U.S. bunion market today.

In Q3 of last year, we transformed